Skip to Content

LifeSci Acquisition Corp.

Merger

  • Date:
  • 9/30/2020
  • Company Name:
  • LifeSci Acquisition Corp.
  • Stock Symbol:
  • LSAC
  • Company Name - Buyer:
  • Vincera Pharma, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 9/29/2020

Case Finder

Locate any case using the tools below.

NEW YORK, September 30, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of LifeSci Acquisition Corp. (NASDAQ: LSAC) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Vincera Pharma, Inc.
 

On September 29, 2020, LifeSci, a special purpose acquisition company, announced that it had signed an agreement to enter into a business combination that would result in Vincera becoming a publicly listed company.  The deal is scheduled to close in the fourth quarter of 2020.
 

Bragar Eagel & Squire is concerned that LifeSci’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for LifeSci’s stockholders.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in LifeSci Acquisition Corp.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: